Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Next Previous
Trial Profile

A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cemiplimab (Primary) ; REGN 7075 (Primary) ; REGN 7075 (Primary) ; Platinum complexes
  • Indications Advanced breast cancer; Cancer metastases; Carcinoma; Colorectal cancer; Head and neck cancer; Liver metastases; Non-small cell lung cancer; Skin cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms COMBINE-EGFR-1
  • Sponsors Regeneron Pharmaceuticals

Most Recent Events

  • 23 Dec 2024 Planned number of patients changed from 769 to 933.
  • 04 Jun 2024 Results of Part 1 data cutoff (Oct 13, 2023, n= 94) presented at the 60th Annual Meeting of the American Society of Clinical Oncology
  • 23 May 2024 According to a Regeneron Pharmaceuticals media release, results for anti-tumor responses in patients with microsatellite stable colorectal cancer will be shared during an oral session at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top